SGLT2 inhibitor empagliflozin could be a new treatment for children with type 2 diabetes: lancet

Published Date: 04 Mar 2023

United States: Empagliflozin could be a new treatment option for children and adolescents with type 2 diabetes, with phase 3 clinical trials showing...

Read Full News

Latest News

Brazil Greenlights Five New Injectable Diabetes Drugs

Brazil's health regulator said ⁠it approved five new injectable GLP-1 drugs for diabetes and obesity treatment, ⁠following the expiration ⁠of Ozempic’s patent in ‌the country.

Statement Offers Guidance Around Incretin Prescribing

Consensus document from three European societies covers nutritional, functional, and psychological considerations for incretin-based therapies in adults.

T1D Onset Before Age 10 Tied to Higher Dementia Risk

Individuals with T1D diagnosed before the age of 10 years face a higher risk of developing dementia than those diagnosed later between ages of 18 and 30 years, a Swedish nationwide study shows.

Yo-Yo Dieting Accelerates Muscle Loss in Middle Age

Repeated episodes of weight loss and regain may be associated with a greater loss of muscle volume than keeping weight stable.

Urinary Incontinence May Lower Exercise Intensity in Women

More than 75% of women in a UK survey reported urinary incontinence, with those experiencing more severe symptoms engaging in less vigorous physical activity, study finds.

ART Regimen Drives Metabolic Variation in Pediatric HIV

The specific antiretroviral therapy regimen—not just HIV status—profoundly shapes the metabolic landscape in virally suppressed children living with HIV.

Todays Updates

Defibrotide Prophylaxis May Reduce SOS Risk After HSCT

A study evaluates whether defibrotide prophylaxis during HSCT reduces the risk for sinusoidal obstruction syndrome in children with relapsed or refractory B-ALL receiving prior inotuzumab.

Todays Updates

Defibrotide Prophylaxis May Reduce SOS Risk After HSCT

A study evaluates whether defibrotide prophylaxis during HSCT reduces the risk for sinusoidal obstruction syndrome in children with relapsed or refractory B-ALL receiving prior inotuzumab.

Latest News

Brazil's health regulator said ⁠it approved five new injectable GLP-1 drugs for diabetes and obesity treatment, ⁠following the expiration ⁠of Ozempic’s patent in ‌the country.

Consensus document from three European societies covers nutritional, functional, and psychological considerations for incretin-based therapies in adults.

Individuals with T1D diagnosed before the age of 10 years face a higher risk of developing dementia than those diagnosed later between ages of 18 and 30 years, a Swedish nationwide study shows.

Repeated episodes of weight loss and regain may be associated with a greater loss of muscle volume than keeping weight stable.

More than 75% of women in a UK survey reported urinary incontinence, with those experiencing more severe symptoms engaging in less vigorous physical activity, study finds.

The specific antiretroviral therapy regimen—not just HIV status—profoundly shapes the metabolic landscape in virally suppressed children living with HIV.

News All Time

Protein, Not Calcium, Key to Osteoporosis Treatment Benefits

Calcium supplementation may not add to the benefits of osteoporosis medications in older women with adequate calcium intake, but a low protein intake is linked to attenuated effects.

Thyroid Abnormalities Often Normalize in Pregnancy

Most pregnant women initially testing positive for subclinical hypothyroidism or hypothyroxinemia do not sustain abnormal thyroid function throughout pregnancy.

Desire to Lose Weight Linked to Unhealthy Behaviors

More than 60% of American adults want to weigh less, and those who do are significantly more likely to skip meals, use non-prescription supplements, or engage in purging behaviors.

Obesity and Cognitive Problems: Understanding the Connection

One can lead to the other. There are a number of reasons why.

Diet Program May Not Match Knee Surgery in Knee OA & Obesity

In patients with obesity and knee osteoarthritis eligible for knee arthroplasty, an intensive dietary weight-loss program is clinically inferior to surgery for patient-reported pain and function.

Increasing GLP-1 Use Raises Muscle Loss Concerns

Incretin mimetic therapy for obesity may reduce muscle mass and bone mineral density, but its effects on physical function and the risk for fractures in older adults remain uncertain.

Spermidine Intake Tied to Liver Health in Obesity and MetS

An increase in dietary spermidine intake over 1 year is associated with improvements in hepatic function and cardiometabolic health in older adults with overweight or obesity and metabolic syndrome.

USG Detects Vagus Nerve Atrophy in Parkinson's Disease

Ultrasound imaging reveals structural changes in the vagus nerve of patients with Parkinson's disease in a meta-analysis.

SGLT2-GLP-1 Combo Little Better Than Monotherapy in T2D

Using both SGLT2 inhibitors and GLP-1 receptor agonists is no more effective than using either drug alone in patients with type 2 diabetes, a new meta-analysis suggests.

Mindfulness-Based Eating Improves Anxiety, Eating Behavior

A mindfulness-based eating intervention improved anxiety, depression, and eating behaviors in adults with obesity and generalized anxiety disorder.

5 Common Lab Results: Why Context Matters

Common laboratory tests can mislead when interpreted without clinical context, highlighting why appropriate test selection matters as much as the results themselves.

Lilly Announces More Next-gen Obesity Drug Data, Plans Q1 2027 FDA Application

Eli Lilly said on Thursday that two more Phase 3 trials of its experimental obesity drug retatrutide showed positive results and it plans to submit ⁠an application to the...

Efforts Address Immune Suppression in Islet Cell Transplants

Updates suggest progress in the development of less-toxic regimens, and in gene editing to eliminate the need for immune suppression entirely.

Helping Patients With Diabetes Utilize Technology

Helping patients overcome fear or anxiety around continuous glucose monitoring may be a hurdle.

Will Semaglutide Prices Drop After 2026 Patent Expirations?

As patents expire, generic injectable semaglutide could become available at a fraction of current branded prices — around $28-$140 per person-year — in about 162 countries by the end of 2026.